Talking stocks, trading, and investing in general

[Concordia]

Watch-- it'll tank tomorrow because the new expectations will be impossible to meet. So will say those who expect.

 

[GreenFrog]

In b4 stock opens up 5%+

 

[brokencycle]

Amazon has been on a tear lately. Almost 40% since August.

 

[lordsuperb]



Amazon has been on a tear lately.  Almost 40% since August.

Do you think it will split?

 

[GreenFrog]

Dat FB pop

 

[GreenFrog]

******* Valeant. What a **** stock.

 

[MSchapiro]

******* Valeant. What a **** stock.

We're talking no real volume here other than one big buyer.

IMO I wouldn't be surprised if there are a few shorting algos at work given the constantly low volume. Whoever the buyer is has me impressed with their trading skill.

 

[GreenFrog]

I'm sure algos and traders are having a field day with the stock but it's also event driven because of the recent senate probe into drug pricing.

Biotech as a whole isn't looking too hot right now.

I should get out and eat my losses (30%+)

 

[MSchapiro]

Biotech as a whole isn't looking too hot right now.

I should get out and eat my losses (30%+)

Why sell at the low point? It's the first time in a long while that valuations aren't looking crazy high.

 

[GreenFrog]

Brah that's my style -- buy high and sell low.

lol in all seriousness I'm just not liking the senatorial probe into drug pricing. That's a probe into your guys' fundamental business model of acquiring drugs and boosting prices.

No bueno.. I don't see how this ends well.

 

[MSchapiro]

Brah that's my style -- buy high and sell low.

lol in all seriousness I'm just not liking the senatorial probe into drug pricing. That's a probe into your guys' fundamental business model of acquiring drugs and boosting prices.

No bueno.. I don't see how this ends well.

I think that is a misinterpretation of the business model. List prices are raised, gross prices are very different. As Mike Pearson has said in the last earnings call, buying mispriced assets isn't really in the business model going forward. It hasn't really been part of the strategy over the last few years either.

In general the best way to think of Valeant is as a downstream pharma player rather than the traditional vertically integrated companies. Excellence in commercialization. This also means revenue flow is relatively durable.

And with that, last comment on this!

 

[brokencycle]

I'm willing to bet the probe goes nowhere.

 

[lawyerdad]



I'm willing to bet the probe goes nowhere.

If I had a nickel for everyone time I've heard that . . ..

 

[djblisk]

I'm glad I didn't take listen to you guys opinions on Visa when I bought some of it. Its been doing well since it stock split.

 

[GreenFrog]

Visa is a strong company. If I had to own one of the credit card companies, it would be Visa hands down over Amex or MasterCard.